HPS masthead
What's New?
. Fukushima Decontamination Report
. CRCPD & CDC Grants for Volunteer Corps
. America's Nuclear Future
. February Newsletter
. Boice Nominated President of NCRP
. February Journal
. February ORS
. Schauer Given the Butterfly Award from Image Gently
. Kase President's Report to IRPA
. IRPA13 Accepting Posters
Upcoming Events
. HPS Midyear - Issues in Waste Management
5-8 February 2012
Dallas, Texas
. NRC Regulatory Information Conference
NRC Regulatory Information Conference
13-15 March 2012
Rockville, Maryland
. NCRP Annual Meeting
12-13 March 2012
Washington, DC
. James E. Turner Memorial Symposium
Call for Abstracts
18-19 April 2012
Oak Ridge Associated Universities, Pollard Auditorium, Oak Ridge, Tennessee
. IRPA13
13-18 May 2012
Glasgow, Scotland
. Canadian Radiation Protection Association (CRPA) Annual Meeting
27-30 May 2012
Halifax, Nova Scotia
. ACS Undergrad Summer Schools
10 June- 20 July 2012
. Nuclear Regulatory Commission Meeting Webcasts
February 2012
Bethesda, Maryland
08 February 2012

Answer to Question #253 Submitted to "Ask the Experts"

Category: Instrumentation and Measurements — Surveys and Measurements (SM)

The following question was answered by an expert in the appropriate field:

Q
I'm interested in finding out the best instrument to use for a patient survey following the administration of a pure beta emitter of 2.3MeV max energy (avg E = 0.33Emax). This agent is tagged to monoclonal antibodies and used in cancer patients. It's 90Sr or 90Y--any ideas here? A determination is required that documents that the patient does not represent a hazard to family or members of the general public following release post administration.
A
One can use a calibrated ionization chamber (such as a portable "cutie pie") which provides an energy-independent measure of dose rate for estimating dose and dose rate at one meter from the patient. In the United States, the Nuclear Regulatory Commission has revised its Part 35 (10 CFR) regulations for the release of patients after an infusion of radioactive material in therapy situations. The objective of the new regulations is to limit the dose rate to any other member of the public to 5 mSv (500 mrem) from radiation emitted by activity in the patient. Zanzonico, Binkert, and Goldsmith (J. Nuc. Med. 40:1024-1028; 1999) have shown that radionuclide therapy with even large amounts (for example, more than 200 mCi) of pure beta-emitters such as Y-90 does not require medical confinement of patients because the dose rates outside the patient from brehmsstrahlung will not exceed the NRC limits.
The information and material posted on this website is intended as general reference information only. Specific facts and circumstances may alter the concepts and applications of materials and information described herein. The information provided is not a substitute for professional advice and should not be relied upon in the absence of such professional advice specific to whatever facts and circumstances are presented in any given situation. Answers are correct at the time they are posted on the Website. Be advised that over time, some requirements could change, new data could be made available, or Internet links could change. For answers that have been posted for several months or longer, please check the current status of the posted information prior to using the responses for specific applications.
image
image
Home Affiliates Ask the Experts Radiation Terms Employment Meetings